At a glance
ClinicalIndex Comparison Record- ✓Histologic or cytologic proof of small cell lung cancer
- ✓Extensive stage disease
- ✓Measurable disease per RECIST criteria; baseline scans within 4 weeks of registration
- ✓ECOG performance status 0, 1, or 2
- ✕CNS metastases; head CT required within 4 weeks to rule out
- ✕Ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness limiting compliance
- ✕History of thrombotic or hemorrhagic disorders
- ✕Arterial thromboembolic events within 6 months (TIA, CVA, unstable angina, MI)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating cisplatin, etoposide, and 2 other interventions for Extensive Stage Small Cell Lung Cancer. Completed, enrolled 65 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving cisplatin and etoposide together with bevacizumab works in treating patients with previously untreated extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or deliver tumor-killing substances to them. Giving chemotherapy with a monoclonal antibody may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Correlative studies